Radar Finance and Economics, Wen Feng Xiuyu, edited by Li Yihui

On April 3, Nuotai Biotech (stock code: 688076) announced that the granule production line of its Lianyungang factory (including the granule production line of workshop 201 and the manual packaging line of workshop 205) has passed the drug GMP compliance inspection of Jiangsu Provincial Drug Administration. The inspection was conducted from February 17 to February 20, 2025, and the inspection concluded that it met the requirements of Good Manufacturing Practice.

The company said that the GMP compliance inspection has further strengthened the production management and quality system of its preparation products, provided a solid guarantee for the continuous development of the preparation market, and has positive significance for the company's future development. At the same time, the company also reminds investors that due to the uncertainty that the production and sales of drugs may be affected by a variety of factors, it is impossible to predict the specific impact of this GMP compliance inspection on the company's recent performance and financial data.

It is worth noting that on October 23, 2024, Nuotai Biotech issued an announcement on the receipt of the notice of filing by the China Securities Regulatory Commission by the company and one of the actual controllers.

Zhao Dezhong, one of the actual controllers of Nuotai Biotech and others, recently received the Notice of Case Filing from the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") (Zheng Jian Case No. 0382024093 and Zheng Jian Case No. 0382024094). According to the Notice of Case Filing, the China Securities Regulatory Commission decided to file the case in accordance with the Securities Law of the People's Republic of China, the Administrative Punishment Law of the People's Republic of China and other laws and regulations.

In this regard, Zhang Yanwei, director of Shanghai Renying Law Firm, told Radar Finance that if the misconduct of a listed company causes losses to investors, the injured investors can claim compensation in accordance with the law. Investors who bought between the listing and October 23, 2024, and held the shares of Nuotai Biotech at the close of trading on October 23, 2024, can register through the official account "Lei Zhu Bar" (Lei Zhu Bar) (Lei Zhu Code: 88) and participate in the claim for free. There are no fees until you receive the claim.

Tianyancha data shows that Nuotai Biology was established on April 3, 2009, with a registered capital of 213.1838 million yuan, the legal representative Tong Ziquan, and the registered address is No. 28, Linpu Road, Lianyungang Economic and Technological Development Zone. The main business is independent R&D and customized R&D and production of peptide drugs and small molecule chemical drugs.

At present, the chairman of the board of directors is Tong Ziquan, the secretary of the board of directors is Zhou Hua, the number of employees is 1,545, and the actual controllers are Zhao Deyi and Zhao Dezhong.

The company has 12 shareholding companies, including Hangzhou Aosaino Pharmaceutical Technology Co., Ltd., Hangzhou Novo Equity Investment Co., Ltd., Hangzhou Aosaino Biotechnology Co., Ltd., Hangzhou Nuotong Biotechnology Co., Ltd., Hangzhou Nuotai Aosaino Pharmaceutical Technology Development Co., Ltd., etc.

In terms of performance, the company's operating income from 2021 to 2023 will be 644 million yuan, 651 million yuan and 1.034 billion yuan respectively, an increase of 13.58%, 1.15% and 58.69% year-on-year respectively. The net profit attributable to the parent company was 115 million yuan, 129 million yuan and 163 million yuan respectively, and the net profit attributable to the parent company increased by -6.52%, 11.89% and 26.20% year-on-year respectively. During the same period, the company's asset-liability ratios were 14.96%, 23.69% and 38.28% respectively.

In terms of risk, Tianyan check information shows that the company has 73 Tianyan risks, 1813 surrounding Tianyan risks, 2 historical Tianyan risks, and 352 early warning reminders.